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Background: Some 7-10% of patients on replacement renal therapy (RRT) are receiving it because of autosomal
dominant polycystic kidney disease (ADPKD). The age at initiation of RRT is expected to increase over time.
Methods: Clinical data of 1,586 patients (7.9%) with ADPKD and 18,447 (92.1%) patients with other nephropathies
were analysed from 1984 through 2009 (1984–1991, 1992–1999 and 2000–2009).
Results: The age at initiation of RRT remained stable over the three periods in the ADPKD group (56.7 ± 10.9
(mean ± SD) vs 57.5 ± 12.1 vs 57.8 ± 13.3 years), whereas it increased significantly in the non-ADPKD group (from
54.8 ± 16.8 to 63.9 ± 16.3 years, p < 0.001). The ratio of males to females was higher for non-ADPKD than for ADPKD
patients (1.6–1.8 vs 1.1–1.2). The prevalence of diabetes was significantly lower in the ADPKD group (6.76% vs
11.89%, p < 0.001), as were most of the co-morbidities studied, with the exception of hypertension. The survival rate
of the ADPKD patients on RRT was higher than that of the non-ADPKD patients (p < 0.001).
Conclusions: Over time neither changes in age nor alterations in male to female ratio have occurred among
ADPKD patients who have started RRT, probably because of the impact of unmodifiable genetic factors in the
absence of a specific treatment.
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ADPKDBackground
Autosomal dominant polycystic kidney disease (ADPKD)
is an inherited disease caused by mutations in two genes,
PKD1 and PKD2, which encode for polycystin 1 and
polycystin 2, respectively: mutations in PKD1 are present
in 85% of cases, and mutations in PKD2 in the remaining
15% [1-3]. The abnormalities in these proteins cause the
appearance and growth of kidney cysts that gradually im-
pair renal function [1]. ADPKD is the cause of chronic
kidney disease (CKD) in 5% of patients undergoing renal
replacement therapy (RRT) in the USA [4], a rate that
rises to 7.9% in our geographic area [5]. In 75-82% of
patients it is additionally associated with hypertension,
which often appears before CKD development [6], and* Correspondence: rtorra@fundacio-puigvert.es
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stated.with other systemic disturbances such as liver cysts, pan-
creatic cysts, brain aneurysms or colonic diverticula.
Progression of CKD in ADPKD basically depends on a
combination of genetic and environmental factors, with
hypertension as a significant prognostic factor. CKD is
more severe and appears earlier in patients with PKD1
gene mutations than in those with PKD2 mutations (mean
age at RRT initiation: 53 and 69 years, respectively) [3,7].
Also, the prognosis is worse for those harbouring a trun-
cating PKD1 mutation compared with those with missense
mutations [8]. Various studies have shown that controlling
hypertension slows down CKD development in patients
with ADPKD [9]. A recent trial, however, has indicated
that reduced glomerular filtration is a function of older
age, and that there are no differences between hyper-
tensive and normotensive patients [10]; hypertensionis
present in nearly 90% of ADPKD patients once they have
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disease: cardiovascular mortality among dialysis patients
is 10–30 times greater than among the general popula-
tion [11]. This fact is explained by the higher prevalence
of classic cardiovascular risk factors in such patients:
hypertension, diabetes, dyslipidaemia and smoking [12].
Diabetic nephropathy and vascular nephropathy are the
primary reasons for initiation of dialysis, specially among
the North American population [4,5]. Moreover, a slow-
down in CKD progression has been verified when cardio-
vascular risk factors are controlled [13]. However, a lower
prevalence of these risk factors has been described in pa-
tients with ADPKD, with the sole exception of hyperten-
sion [14], which is present in nearly 90% of ADPKD
patients once they have renal failure.
The objective of this observational study is to analyse
the epidemiological, clinical and survival changes that
occur over time in ADPKD patients who have started
RRT, as compared with non-ADPKD patients on RRT
during the last 25 years.
Methods
Study design
The data analysed came from the Catalan Renal Patients
Registry, created in 1984 with the aim of assisting the
Renal Failure Care Programme in planning its resources.
This is a mandatory reporting registry for all patients
in Catalonia, a Spanish autonomous community with
over 7 million inhabitants. This registry collects socio-
demographic and clinical data of all patients who start
RRT, including haemodialysis, peritoneal dialysis and
renal transplantation and excluding transient patients.
The quality of the information is ensured by means of
mechanisms of validation and processing of the periodically
reported cases, and the performance of a yearly follow-up
of all active cases as of 31 December.
Patients who started RRT between 1984 and 2009 were
considered and divided into two groups: patients on RRT
because of ADPKD [code 41 in the ERA-EDTA classifica-
tion of Primary Renal Disease (PRD)], and the remaining
patients with other reasons for initiation of RRT (remaining
ERA-EDTA PRD codes), called the non-ADPKD group.
The diagnosis of ADPKD was specified by the clinician at
the time of reporting to the Registry, based on the patient’s
family history and on ultrasound criteria compatible with
the disease. Patients actively on dialysis at 31 December
2009 were also considered when describing the current
situation of patients.
Clinical and demographic data
The study follow-up time was divided into three periods
of RRT initiation: 1984–1991, 1992–1999 and 2000–2009.
The variables analysed were gender and age, both
upon RRT initiation and at the end of the RRT study,and the presence of associated diseases in the 1992–2009
cases. These associated diseases included: hypertension
(defined as blood pressure over 140/90), diabetes mellitus,
ischaemic or non-ischaemic heart disease, arrhythmia,
cerebrovascular disease, peripheral vascular disease, malig-
nancies, chronic respiratory disease, tuberculosis, chronic
liver disease, gastroduodenal disorders, bowel disease and
joint disease. These co-morbidities were analysed from
2000 to 2009 because from 1992 to 1999 it was not
compulsory to notify them and therefore data were not
complete.
The first vascular access (temporary catheter, tunnelled
catheter, arteriovenous fistula or prosthetic graft) was also
analysed in patients who started haemodialysis between
1997 and 2009, divided into two periods: 1997–2003 and
2004–2009.
In patients actively on dialysis as of 31 December 2009,
we studied: percentage of patients with hepatitis C virus,
percentage of patients who received erythropoietin, and
C-reactive protein (CRP) levels in mg/l (CRP >10 mg/l
or <10 mg/l), according to the standard method.
In patients who had received a kidney transplant we
analysed the type of donor (living or cadaveric), the time
elapsed since start of dialysis to transplant surgery, and
the age at the time of transplantation.
Regarding those patients who died while on RRT, we
analysed their age at the time of death and the causes of
death. We classified the causes of death as follows: cardiac,
vascular, infectious, cancer, hepatic, social, other and un-
known. Survival rates of patients with and without
ADPKD during the first 3 years after initiation of RRT,
and also patient and renal graft survival from the time of
transplantation, when applicable, were also considered.
Statistical analysis
Software STATA11 was used for statistical analysis. Chi-
square test was applied to analyse qualitative variables, and
Student’s t-test for the comparison of means of the quanti-
tative variable. The log-rank test was used to verify the
survival rates. Statistical significance was set at p < 0.05.
Limitations
Only the information contained in the fields of the
mandatory reporting registry of the Catalan Renal Patients
Registry has been used in this observational study. Other
interesting information for the purpose of this study, but
not included in these forms, was not available. For ex-
ample, data relating to the period prior to the onset of
end-stage renal disease (ESRD) were not available as the
study is based on a registry of ESRD.
Results
A total of 20,033 patients in whom RRT had been initi-
ated were registered between 1984 and 2009: 1,586 of
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nephropathies.
As shown by Table 1 and Figure 1, age at initiation of
RRT in the ADPKD group was significantly lower than
in the remaining patients, for both males and females
(p < 0.001). Among ADPKD patients, the mean age over
the three periods investigated was 56.7 ± 10.9, 57.5 ± 12.1
and 57.8 ± 13.3 years, respectively, with no significant
differences (p = 0.37). Among non-ADPKD patients, how-
ever, the mean age increased significantly (p < 0.001) as
follows: from 54.8 ± 16.8 years in the first period to 61.7 ±
16.2 years in the second period to 63.9 ± 16.3 years in the
third period.
Both groups contained more males than females. The
ADPKD group comprised 837 (52.8%) men and 749
(47.2%) women, while the non-ADPKD group comprised
11,641 (63.1%) men and 6,806 (36.9%) women. No sig-
nificant differences were identified regarding the inci-
dence of males and females at RRT initiation in the
ADPKD group (ratio, 1.1–1.2), but in the non-ADPKD
group the number of men who started RRT was signifi-
cantly higher than the number of women (ratio, 1.6–1.8)
(Figure 2).
Table 2 shows that cardiovascular diseases, malignancies,
chronic respiratory disorders and joint diseases are signifi-
cantly less frequent among ADPKD patients (p < 0.001).
Among the cardiovascular risk factors analysed, diabetes
was significantly less frequent (p < 0.001) in ADPKD pa-
tients than in the non-ADPKD group (6.76% vs 11.89%),
and no differences were observed regarding the prevalence
of hypertension (86.24% vs 84.20%).
Most of the patients started RRT with haemodialysis
in both groups. However, a prevalence analysis dated 31
December 2009 showed that transplantation was theTable 1 Clinical features of ADPKD and non-ADPKD patients o
ADPKD (n: 1586
Age (years) at initiation of RRT in men 57.2 ± 12.7
Age (years) at initiation of RRT in women 57.8 ± 12.0
First choice of RRT (%) HD 91.1%
TX 2.5%
PD 6.4%
RRT strategy at 31.12.2009 (%)1 HD 31.8%
TX 65.4%
PD 2.8%
Time from initiation of RRT to TX (years)2 2.9 (2.7-3.1)
Age at TX (years)2 53.5 (52.9-54.0)
Treated with ESA (%)1 77.9%
HCV (%)1 5.1%
CRP (<10 mg/l)1 71.7%
ADPKD Autosomal dominant polycystic kidney disease, RRT renal replacement thera
ESA erythropoiesis stimulating agents, HCV hepatitis C virus, CRP C-reactive protein.
1Patients actively on RRT at 31 December 2009, 295% confidence intervals.most prevalent situation among ADPKD patients: 65.4%
in the ADPKD group and 49.3% in the non-ADPKD group.
The analysis also showed that fewer patients with ADPKD
required erythropoietin (p < 0.001) and that they had a
lower prevalence of hepatitis C virus (p < 0.001). The CRP
levels were lower in the ADPKD group, but this difference
did not attain statistical significance (p = 0.124) (Table 1).
Significant differences (p < 0.001) in the use of different
types of vascular access at initiation of haemodialysis were
also observed in both the periods analysed (1997–2003
and 2004–2009) in the ADPKD group. An increase in
arteriovenous fistulae was observed (74.3% vs 78.6%), and
the same was true for tunnelled catheters (2.6% vs 7.5%)
and prostheses (2.6% vs 7.5%); there was also a reduction
in the number of temporary catheters (22.3% vs 11.7%).
When analysing patients with kidney transplants, the
number of living donors increased only over the most re-
cent years (10–11 per year), even though cadaveric trans-
plants continue to be more frequent (95.1% of all kidney
transplants).
The primary causes of death during the study period
were cardiovascular, followed by infections, in both groups
(Table 3). No significant differences were observed regard-
ing the age of death between ADPKD and non-ADPKD
patients (69.0 ± 10.0 vs 69.4 ± 12.6 years) (p = 0.41). Sur-
vival over the first 3 years of RRT was higher in the
ADPKD group (p < 0.001) as well as in the subgroup of
kidney-transplanted patients (p < 0.03) (Table 4; Figure 3).
The renal graft survival was also longer in the ADPKD
group (p < 0.001) (Table 4; Figure 4a and 4b).
Discussion
Although there is no specific treatment for ADPKD as
yet, the therapeutic advances to slow down CKD mightn RRT
) Non ADPKD (n: 18,447) p
60.9 ± 16.6 <0.001
62.5 ± 17.0 <0.001
HD 89.4% <0.01
TX 8.5%
PD 2.0%
HD 46.9% <0.001
TX 49.3%
PD 3.8%
3.1 (3.0-3.1) p = 0.09
44.6 (44.2-44.9) <0.001
91.9% <0.001
10.0% <0.001
66.9% 0.124
py, HD haemodialysis, TX transplantation, PD peritoneal dialysis,
Figure 1 Mean age at initiation of RRT for ADPKD and non-ADPKD
patients for the three different periods of the study (p < 0.01).
Table 2 Associated diseases in patients with and without
ADPKD (2000–2009)
Disease ADPKD% (n)
Non-ADPKD
% (n) p
Hypertension 86.24 (589) 84.20 (7567) 0.158
Diabetes mellitus 6.02 (42) 12.45 (1143) <0.001
Ischaemic cardiopathy 9.42 (65) 21.66 (1954) <0.001
Other cardiomyopathy 9.83 (68) 28.43 (2566) <0.001
Arrhythmias 6.08 (42) 17.37 (1568) <0.001
Cerebrovascular 8.16 (56) 13.65 (1230) <0.001
Vascular 6.41 (44) 23.0 (2072) <0.001
Cancer 4.93 (34) 11.36 (1026) <0.001
Chronic respiratory 7.14 (49) 18.20 (1639) <0.001
Tuberculosis 0.44 (3) 1.22 (110) 0.065
Liver 3.6 (25) 6.65 (600) 0.002
Gastroduodenal 7.15 (49) 10.69 (963) 0.004
Intestinal 4.82 (33) 6.35 (572) 0.110
Arthropathy 13.99 (96) 23.97 (2157) <0.001
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ADPKD patients will have been delayed until a later age.
Our data, however, show that the age at initiation of
RRT in these patients has not varied since 1984. This re-
sult is in concordance with other articles [15], but some
publications [16-18] do indicate that the age at initiation
of RRT in ADPKD patients has indeed increased.
According to Orskov et al. [16], age at onset of ESRD
among their 693 ADPKD patients, followed up for 18 years
(divided into three periods), rose from 55.9 (1990–1995)
to 60.6 years (2002–2007), though these findings are sub-
ject to a potential bias, given the increasing number of pa-
tients in each period and especially the rise in the number
of women.
The prognosis of CKD patients who start with RRT
has improved over the last few years [19,20]. In the
European Registry, the percentage of patients older than
65 who started RRT increased from 22% in 1980 to 55%
in 2005 [21], and this may be attributed to a better con-
trol of cardiovascular risk factors. We have not been ableFigure 2 Male to female ratio in the ADPKD and non-ADPKD
populations on RRT, in the three periods of the study.to find in the literature any studies comparing the age at
onset of ESRD between patients with and patients with-
out ADPKD. Based on our own results, we would stress
that while, over the three periods examined, the age at
initiation of RRT in non-ADPKD patients rose by more
than 9 years, no such change occurred among ADPKD
patients.
Epidemiological studies indicate that within the general
population, the prevalence of men undergoing RRT is
higher than that of women, in accordance with our find-
ings [21]. These data are in agreement with some other
publications that associate male gender with earlier initi-
ation of RRT in ADPKD patients [22,23]. In contrast, and
in accordance with other studies [16,24], we found no sig-
nificant gender differences in relation to age at initiation
of RRT. Our data show that male gender is a risk factorTable 3 Causes of death of ADPKD and non-ADPKD
patients after starting RRT
Cause of death ADPKD% (n)
Non-ADPKD
% (n)
Age1
(ADPKD vs non-ADPKD)
Cardiac 26.17 (241) 31.15 (3912) 69.1 ± 9.8 vs 68.9 ± 12.1
Vascular 18.35 (169) 16.52 (2075) 68.8 ± 10.6 vs 69.4 ± 12.6
Infection 14.44 (133) 15.57 (1955) 68.8 ± 9.6 vs 67.9 ± 13.6
Cancer 9.55 (88) 8.30 (1043) 67.5 ± 9.3 vs 67.6 ± 12.2
Hepatic 3.04 (28) 1.84 (231) 64.1 ± 2.2 vs 61.1 ± 0.9
Social2 3.47 (32) 6.04 (758) 75.1 ± 6.6 vs 75.7 ± 10.4
Other 12.7 (117) 9.65 (1212) 71.1 ± 9.9 vs 71.6 ± 12.4
Unknown 12.27 (113) 10.93 (1373) 67.9 ± 9.7 vs 70.0 ± 12.3
1No statistically significant differences when comparing the mean age at death
of ADPKD patients versus Non ADPKD patients (p = 0.41).
2The term “social” as cause of death means: rejection of RRT by the patient
or suicide.
Table 4 Survival rates in ADPKD and non-ADPKD patients
during the first three years
Years ADPKD (%) Non ADPKD (%) p
Patients on RRT 1st 95 85 <0.001
2nd 91 75
3rd 88 66
Transplanted patients 1st 96.0 95.4 0.03
2nd 94.8 93.6
3rd 93.4 91.9
Graft survival 1st 90.0 87.4 <0.001
2nd 88.4 83.7
3rd 86.2 80.1%
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1.6-1.8), but not among ADPKD patients (ratio, 1.1-1.2).
Although most of our ADPKD patients started RRT
with haemodialysis, the prevalence study revealed kidney
transplantation to be the most widely used method, as
expected based on the age at onset of ESRD in this
population. The sparse prescription of peritoneal dialysis
among ADPKD patients could be due to large kidneys,
to the presence of colonic diverticula, to hernias or to
massive polycystic liver disease. However, peritoneal dia-
lysis is a first-line technique for this disease, as has been
shown by several studies that revealed no differences
concerning survival or risk of peritonitis [25,26]. On the
contrary, it was found that ADPKD patients on periton-
eal dialysis had a higher survival rate than those on
haemodialysis [25].
The factors related to greater ADPKD severity are pri-
marily carrying a PKD1 mutation, especially if truncating,
and hypertension [3,8,27]. Other relevant factors include:
age at diagnosis [28,29], increased number and volume of
the cysts, left ventricle hypertrophy [30], proteinuria [31],
haematuria, microalbuminuria, hyperuricaemia [32], low0%
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Figure 3 Kaplan-Meier plot of survival for ADPKD and non-ADPKD paHDL-cholesterol levels, high urinary sodium and an
increase in urinary osmolality [33]. Cardiovascular risk
factors increase the rate CKD progression [4,12], with
both entities boosting each other, giving rise to a
cardiorenal syndrome. ADPKD is a typical model of type
IV cardiorenal syndrome [34], as the cause of CKD is pri-
mary renal failure and secondary cardiovascular involve-
ment. We have observed a lower prevalence of diabetes
among patients with ADPKD, but the differences in com-
parison with non-ADKPD patients have not been found to
be significant with regard to hypertension, similarly to
other studies [14,35-37]. The data published on associated
diseases in ADPKD and non-ADPKD patients are either
incomplete [38] or have concerned only cardiovascular
events [39]. We have observed that cardiovascular dis-
eases, malignancies and respiratory diseases are more fre-
quent among non-ADPKD patients on RRT. This higher
rate of co-morbidities in non-ADPKD patients could be
explained by the higher prevalence of diabetes and by ini-
tiation of RRT at an older age. The lower cardiovascular
morbidity among ADPKD patients could be associated
with higher haemoglobin levels in this group [35]. In
correspondence with Abbott and Agodoa’s results [35],
we found that fewer ADPKD patients on dialysis need
erythropoietin compared with the non-ADPKD group
(77.9% vs 91.9%). CKD favours a chronic inflammation
status with increased inflammatory markers such as C-
reactive protein (CRP) [37]. In accordance with other
articles, we observed no significant differences be-
tween the groups with regard to CRP levels, although
they were lower among ADPKD patients on dialysis,
probably owing to the lower prevalence of associated
diseases [40].
The hugely significant genetic factor in ADPKD
could be related to a fatal renal prognosis that is quite
difficult to modify with the currently available2 3
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Non ADPKD
tients on RRT.
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Figure 4 Kaplan-Meier plots of survival among transplanted patients (a) and graft survival (b) in the ADPKD and non-ADPKD populations.
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tors. Stimulation of the renin-angiotensin system
(RAS) has been associated with a sombre ADPKD
prognosis owing to faster growth of the renal cysts
[24]. The HALT trial is underway to elucidate the con-
tribution of angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers (ARBs) and
the strict control of hypertension to the slowing of de-
cline in renal function [41]. Increased use of RAS-
blocking anti-hypertensive drugs could imply that
ADPKD patients will start on RRT later and later [16].
However, although ACEIs and ARBs are widely used
for ADPKD in our population (specific data not avail-
able), this assumption is not in accordance with our
findings.
Kidney transplantation is for the moment the best
therapeutic choice for ADPKD patients with ESRD.
Longer survival of both patient and graft has been ob-
served in recipients of kidney transplants with ADPKD[20,42], in agreement with our results. This increase in
survival could be explained by the ADPKD patients’
younger age, lower rate of diabetes, lower prevalence of
dyslipidaemia and anaemia, and also a lower prevalence
of co-morbidities, mainly cardiovascular ones. It has not
been possible to show that immunological factors may
play a role in this survival difference. No explanation for
a longer graft survival, other than the own patient’s sur-
vival, is available. The relatively low but increasing per-
centage of pre-emptive living donor transplantation is
due to the transplantation policies of Spain, which has a
highly successful programme for cadaveric transplant-
ation and is encouraging living donor transplantation to
overcome the current relative scarcity of cadaveric
donors.
The primary cause of death among ADPKD patients on
RRT, in our cohort, is cardiovascular disease, followed by
infections, as reported by several other authors [43-45].
Various articles have shown higher survival of ADPKD
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which concurs with our data [46,47]. We found no differ-
ences as to the age of death, even though ADPKD patients
started RRT earlier than non-ADPKD patients; this indi-
cates a longer survival of ADPKD patients on RRT. Longer
survival of ADPKD patients has been associated with:
starting RRT at a younger age, lower prevalence of the car-
diovascular risk factors and higher haemoglobin levels, all
of which are factors applicable to our results [48,49]. In
another study, ADPKD patients on RRT still showed a
higher survival rate than diabetes-free non-ADPKD
patients [50], though such a difference was not observed
by other authors [51].
Conclusion
Over the last few years initiation of RRT has been delayed
in non-ADPKD patients owing to cardiovascular risk fac-
tors being better controlled. ADPKD patients have a lower
prevalence of cardiovascular risk factors and also less co-
morbidity, which favours longer survival. Still, over time
no changes in age at onset of ESRD have occurred among
ADPKD patients who have started RRT, probably because
of the impact of unmodifiable genetic factors in the ab-
sence of a specific treatment. However, there is reasonable
hope that disease progression in patients with ADPKD
can be delayed with newer therapeutic approaches which
are currently being tested.
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